[Onscreen text]
Once every five years, a manufacturing plant in Los Angeles stops all regular production to make a life-changing medicine for the ~200 babies globally who contract infant botulism each year.

[John Sisto, former Takeda employee & grandfather of infant botulism patient]
I do understand, from a manufacturing plant, you’re interrupting usual manufacturing lines.

You’re stopping product that you normally make here for this batch.

But I do want to say thank you for doing this, Takeda and the L.A. plant, because you actually saved my granddaughter’s life.

[Onscreen text]
BabyBIG (Human Botulism Immune Globulin Intravenous) is a plasma-derived therapy produced through a not-for-profit partnership between Takeda and the California Department of Public Health.

To date, eight lots of BabyBIG have been manufactured to help meet the needs of infants receiving treatment for botulism around the world.

[Giles Platford, President, Plasma-Derived Therapies Business Unit]
This is an important event for us.

Not because it’s a commercial driver
value for Takeda, but because it’s so true to

who we are as a company, as a truly
patient-centric, values-led company.

And nothing expresses that
more than an initiative like this.

[Thomas Wozniewski, Global Manufacturing & Supply Officer]
But I think that’s why we are here.

That’s why we work day and night.

And again, I want to congratulate
and thank a lot to the team.

You do a fantastic job.

And really we thank you a lot.